GlassScriptPhysician profile
Matthew C Young
NPI 1821060062
$269,693.05
in general payments reported to CMS, 2019-2025
75 companies · $1,980 in 2025
The $1,980 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $21K · 2021: $88K · 2022: $61K · 2023: $65K · 2024: $2,028 · 2025: $1,980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Travel and Lodging: $13K · Food and Beverage: $7,689 · Honoraria: $5,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,200.00 |
| Travel and Lodging | $12,895.99 |
| Food and Beverage | $7,689.40 |
| Honoraria | $5,008.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $227,212.93 | 2019-2023 | Korlym |
| Zimmer Biomet Holdings, INC. | $17,945.00 | 2019 | |
| Allergan, INC. | $11,424.14 | 2019-2020 | |
| Abbvie INC. | $1,536.45 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,331.77 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Amgen INC. | $908.33 | 2019-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $882.87 | 2019-2025 | Kisunla, Mounjaro, Zepbound |
| Novo Nordisk INC | $865.90 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $858.01 | 2020-2025 | Glassia, Aralast, Trintellix |
| Pfizer INC. | $610.06 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $462.09 | 2019-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $400.65 | 2022-2025 | Rexulti, Brintellix, Vyepti |
| Kowa Pharmaceuticals America, INC. | $340.73 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.05 | 2019-2025 | Xifaxan |
| Antares Pharma, INC. | $245.90 | 2021-2025 | Xyosted, Nocdurna, Tlando |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.